Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer

In this episode, experts discuss practical, patient-centered strategies for CDK4/6 inhibitor therapy in HR-positive/HER2-negative breast cancer, with a focus on adverse event monitoring and management, dose modifications, adherence support, and preventing early discontinuation. The discussion also highlights real-world approaches to counseling, multidisciplinary coordination, and helping patients stay on therapy long term.